Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
It is well known the efficacy of 5% 5-fluoruracil for multiple and superficial actinic keratosis (AKs)treatment. Recently its additional benefit for advanced and severe photoaging while treating Aks was reported.
The aim of this study is to compare the efficacy and safety of the two modalities of 5% 5-FU use for forearms photoaging.
The use of 5% 5-fluorouracil (5-FU) cream, twice a day, during 3 weeks represents a classic treatment for multiple and superficial AKs. The main adverse event is the severe skin irritation leading to interruption of the treatment in some cases. In the last decade a superficial pulse-peeling using it as agent in sequential applications was described. This modality of treatment has been demonstrated efficacy and better tolerability.
The improvement of the overall aspect of photodamaged skin is observed while treating multiple AKs.
There are no comparative study between the two types of 5% 5-FU use. So that is the purpose of our clinical trial.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 5% 5-fluoruracil cream | Active Comparator | 30 patients will use 5% 5-fluoruracil cream, twice a day, during 3 weeks, in one randomized forearm |
|
| 5% 5-fluoruracil peeling | Active Comparator | The same 30 patients will be submitted to 4 applications of 5% 5-fluoruracil superficial peeling in the other forearm |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 5-fluoruracil | Drug | 5% 5-fluoruracil cream, twice a day, during 3 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Photographic Evaluation | Photographic blinded evaluation by two independent observers, comparing modifications of forearms skin overall aspect before and after 60 and 180 days of the treatments. The following 5 point scale will be used: -2=much worse; -1=worse; 0=inlatered; 1=better, 2= much better | 0, 60, 180 days |
| Change in Microscopic Evaluation | Skin biopsies will be performed and coloration by hematoxilin-eosin, Verhoeff, Tricromio Masson , Picrosirius and biomarkers (p53, bcl2, collagen 1)will be used. The modifications on corneal layer and epidermal thickness, dermal elastotic material and collagen deposition and biomarkers expression will be evaluated by digital quantitative analysis, comparing the findings before (day 0) and after (day 180)treatments. | 0, 180 days |
| Measure | Description | Time Frame |
|---|---|---|
| Inflammatory Skin Reaction | Comparison between treatments on inflammatory skin reaction will be performed by expression of interleucin-1, using immunohistochemistry | 30 day |
| Occurence and Evaluation of Adverse Events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Topical treatment with:
Treatment by chemical peeling, microdermabrasion and non-ablative laser in the last 3 months;
Treatment with systemic retinoid in the last 6 months ;
Chemotherapy in the last 3 months;
Hypersensibility to parabens;
Infectious or inflammatory dermatosis on forearms;
Clinical evidence of immunosuppression and
Presence of photodermatosis
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Edileia Bagatin, phD | Contact | 55-11-94448848 | edileia_bagatin@yahoo.com.br |
| Name | Affiliation | Role |
|---|---|---|
| Ediléia Bagatin, PhD | Professor | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Edileia Bagatin | Recruiting | São Paulo | São Paulo | 04075-000 | Brazil |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Aug 21, 2017 | |
| Reset | Mar 8, 2018 | |
| Release | Jun 1, 2019 | |
| Reset | Jul 26, 2019 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Aug 21, 2017 | Mar 8, 2018 | |||
| Jun 1, 2019 |
| ID | Term |
|---|---|
| D055623 | Keratosis, Actinic |
| D063646 | Carcinogenesis |
| ID | Term |
|---|---|
| D011230 | Precancerous Conditions |
| D009369 | Neoplasms |
| D007642 | Keratosis |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013812 | Therapeutics |
| D003358 | Cosmetics |
| ID | Term |
|---|---|
| D020313 | Specialty Uses of Chemicals |
| D020164 | Chemical Actions and Uses |
| D006795 | Household Products |
| D013676 | Technology, Industry, and Agriculture |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 5-fluoruracil | Procedure | The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators) |
|
|
Predictable and unpredictable side effects and their intensity related by patient and/or observed by investigator will be analized and compared between the treatments
| 30, 60, 180 days |
| Change in Patient Opinion | Patient opinion concerning modification on forearms skin overall aspect, using a 5 point scale: -2=much worse; -1=worse; 0=inaltered; 1=better, 2= much better, comparing day 0 to 60, 60 to 180 and 0 to 180. | 0, 30, 60, 180 days |
| Change in Investigator Clinical Evaluation | Investigator efficacy evaluation through actinic keratosis counting, on days 0, 30, 60 and 180 as weel as modification on forearms skin overall aspect. That will be performed by comparision of skin examination on days 60 and 180 to photography captured on days 0 and 60, i.e, 0 to 60, 60 to 180 and 0 to 180, using a 5 point scale: -2=much worse; -1=worse; 0=inaltered; 1=better, 2= much better | 0, 30, 60, 180 days |
| Change in Forearm Photoaging Classification | A classification will be created and validated by investigators and five independent observers previously to classify forearm photoaging. After validation it will be applied to study subjects on days 0, 60 and 180 to evaluate modification on the forearm photoaging grade for each tretament. | 0, 60, 180 days |
| Jul 26, 2019 |
| D017437 |
| Skin and Connective Tissue Diseases |
| D009385 | Neoplastic Processes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |